Crohn Disease (CD): Clinical Trials

11 trials for Crohn Disease (CD), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 recruiting, 2 not yet recruiting, 1 enrolling by invitation, 1 unknown. 11 Phase 2, 4 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 211Recruiting 7, Not yet recruiting 2, Enrolling by invitation 1, Unknown 1
Phase 14Recruiting 3, Not yet recruiting 1
Phase 31Enrolling by invitation 1

Follow Crohn Disease (CD): new trials by email Literature Review of Crohn Disease (CD) trials Research Report on Crohn Disease (CD)

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
HB-adMSCs for the Treatment of Crohn's Disease
HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells, 0.9% sodium chloride - Crohn Disease (CD)
Phase 2RecruitingHope Biosciences Research Foundation462026-07-142026-08-06
DB-3Q for the Treatment of Medically Refractory Crohn's Disease
DB-3Q, Placebo - Crohn Disease (CD)
Phase 2RecruitingDirect Biologics, LLC362026-06-012026-09-01
Clostridium Butyricum in Stenosing Crohn's Disease
Clostridum Butyricum Capsule, Trehalose - Crohn Disease (CD)
Phase 1 / Phase 2RecruitingSan Giovanni Addolorata Hospital402026-05-082026-09-04
Modafinil For Fatigue in IBD: A Feasibility Randomised Controlled Trial
Modafinil, Placebo - Crohn Disease (CD), Ulcerative Colitis (UC)
Phase 2Not yet recruitingImperial College London702026-02-012025-12-22
Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease
25mg adalimumab-680LT and 15/25 mg risankizumab-800CW, Adalimumab-680LT 25mg, Risankizumab-800CW 15 mg/25 mg - Ulcerative Colitis (UC), Crohn Disease (CD)
Phase 1 / Phase 2Not yet recruitingUniversity Medical Center Groningen302026-01-152026-01-14
Tolerance of Local Administration of Cryopreserved Autologous Stromal Vascular Fraction Combined With Micrograft for the Treatment of Refractory Ano-perineal Fistulas in Crohn's Disease
injection of thawed SVF - Crohn Disease (CD)
Phase 1 / Phase 2RecruitingAssistance Publique Hopitaux De Marseille252025-12-302026-06-05
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
Tirzepatide, Standard of care treatment - Crohn Disease (CD)
Phase 2RecruitingWashington University School of Medicine602025-05-132026-06-05
Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease
After surgery for Crohn's disease, eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with or without SoC treatment (based on investigator decision) for up to 24 weeks - Crohn Disease (CD)
Phase 2RecruitingMadeleine Bezault802025-03-312026-11-18
Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease
Risankizumab-800CW 4.5 mg, Risankizumab-800CW 15 mg, Risankizumab-800CW 25 mg - Ulcerative Colitis (UC), Crohn Disease (CD)
Phase 1 / Phase 2RecruitingUniversity Medical Center Groningen182024-11-082025-03-05
Evaluation of the Efficacy of Local Budesonide Treatment in Children with Crohn's Disease Located in the Esophagus And/or Stomach And/or Duodenum
budesonide, omeprazole (proton pump inhibitor) - Crohn Disease (CD)
Phase 2 / Phase 3Enrolling by invitationMedical University of Warsaw1142024-07-302024-12-06
FAPi-PET Imaging of in Vivo Fibrosis in Inflammatory Bowel Disease Patients
68Ga-FAPi-46 - IBD (Inflammatory Bowel Disease), Crohn Disease (CD)
Phase 2UnknownDalia Lartey202023-08-312024-09-19

Narrower conditions

Crohn Disease (11)  ·  Colitis, Ulcerative (4)  ·  Inflammatory Bowel Diseases (4)  ·  Fatigue (1)

Broader conditions

Digestive System Diseases (11)  ·  Gastroenteritis (11)  ·  Gastrointestinal Diseases (11)  ·  Intestinal Diseases (11)  ·  Inflammatory Bowel Diseases (7)  ·  Colitis (4)  ·  Colonic Diseases (4)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Signs and Symptoms (1)

Interventions

Budesonide (1)  ·  Modafinil (1)  ·  Omeprazole (1)  ·  Postoperative Period (1)  ·  Proton Pump Inhibitors (1)  ·  Sodium Chloride (1)  ·  Tirzepatide (1)  ·  Trehalose (1)

Sponsors

University Medical Center Groningen (2)  ·  Assistance Publique Hopitaux De Marseille (1)  ·  Dalia Lartey (1)  ·  Direct Biologics, LLC (1)  ·  Hope Biosciences Research Foundation (1)  ·  Imperial College London (1)  ·  Madeleine Bezault (1)  ·  Medical University of Warsaw (1)  ·  San Giovanni Addolorata Hospital (1)  ·  Washington University School of Medicine (1)

Countries

Netherlands (3)  ·  United States (3)  ·  France (2)  ·  Italy (1)  ·  Poland (1)  ·  United Kingdom (1)

Top investigators

Andres Yarur, MD (1)  ·  Calum Moulton (1)  ·  Louis Cohen, MD (1)  ·  Mark Lowenberg, MD PhD (1)  ·  Matthieu Allez (1)  ·  Parakkal Deepak, MBBS, MS (1)  ·  Thanh Cheng, MD (1)

NIH funding

2025 (1)